BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the ...
Goldman Sachs reported a 1.21 percent return for the Tactical Tilt Overlay Fund in a strong third quarter. Review these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback